Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

64.20USD
12:04pm EDT
Change (% chg)

$0.32 (+0.50%)
Prev Close
$63.88
Open
$64.05
Day's High
$64.52
Day's Low
$63.91
Volume
811,801
Avg. Vol
2,755,213
52-wk High
$66.80
52-wk Low
$58.29

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $174,223.41
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.94

Financials

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission

* AstraZeneca and Merck rapidly advance LYNPARZA (olaparib) in Japan with a second regulatory submission

7:05am EDT

BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan

* ‍ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION​

2:28am EDT

Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

Drugmaker Merck & Co Inc , moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.

Oct 20 2017

UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

Oct 20 Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.

Oct 20 2017

Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care

Oct 20 Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.

Oct 20 2017

Merck cyber attack may cost insurers $275 million: Verisk's PCS

NEW YORK Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit.

Oct 19 2017

CORRECTED-Merck cyber attack may cost insurers $275 mln -Verisk's PCS

NEW YORK, Oct 19 Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit.

Oct 19 2017

BRIEF-U.S. FDA accepts regulatory submission for lynparza

* U.S. FDA accepts regulatory submission for lynparza® (olaparib) in metastatic breast cancer and grants priority review

Oct 18 2017

BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA

* Merck’s KEYTRUDA® (pembrolizumab) more than doubled median overall survival compared to chemotherapy after two years of follow up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1

Oct 18 2017

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

Oct 18 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $143.99 +1.59
Pfizer Inc. (PFE.N) $36.51 +0.09
AbbVie Inc (ABBV.N) $95.07 -1.03
Eli Lilly and Co (LLY.N) $87.57 +0.34
Bristol-Myers Squibb Co (BMY.N) $64.38 -0.04
Bristol-Myers Squibb Co (BMYMP.PK) $1,088.70 +38.70

Earnings vs. Estimates